GRCE Stock — Grace Therapeutics, Inc.: Metrics

Market overview

2 metrics

Share price

$2.10

Market cap

$44.18M

Price action

19 metrics

Price change (1W)

-0.9%

Price change (30D)

-0.5%

Price change (3M)

-8.7%

Price change (6M)

-45.6%

Price change (YTD)

-39.3%

Price change (1Y)

-31.4%

Trailing year

Price change (5Y)

—

52-week high

$5.13

52-week low

$2.07

Change from 52-week high

-59.1%

Change from 52-week low

+1.4%

Annualized volatility

70.1%

Beta

0.9

RSI (14D)

42.3

Price vs SMA 50

-6.5%

Price vs SMA 200

-31.7%

Avg volume (3M)

216,717

Relative volume

0.9

Average dollar volume

$487,293

Company

3 metrics

Sector

Healthcare

Industry

Biotechnology

Shares outstanding

21.04M

Valuation

12 metrics

P / E (TTM)

—

Trailing earnings

PEG ratio

—

EV / revenue

—

EV / EBITDA

—

EV / EBIT

—

P / sales

384.1×

reciprocal yield 0.3%

P / book

—

FCF yield

—

TTM · current market cap

Buyback yield

—

P / FCF

—

P / operating cash flow

—

Earnings yield

—

Historical valuation

8 metrics

P / E historical average (3Y)

—

P / E historical average (5Y)

—

EV / revenue historical average (3Y)

—

EV / revenue historical average (5Y)

—

EV / EBIT historical average (3Y)

—

EV / EBIT historical average (5Y)

—

EV / EBITDA historical average (3Y)

—

EV / EBITDA historical average (5Y)

—

Dividends & buybacks

7 metrics

Dividend yield

—

Trailing 12 months

Payout ratio

—

Shareholder yield

—

Dividend / share (TTM)

—

Dividend growth YoY

—

Dividend growth streak

—

Last ex-dividend

—

Earnings calendar

2 metrics

Next earnings

—

Last earnings

2023-02-14

Profitability

9 metrics

Gross margin

65.2%

Operating margin

—

Trailing 12 months

Net margin

—

Gross profit (TTM)

—

Operating profit (TTM)

—

Net income (TTM)

—

Trailing 12 months

Diluted EPS (TTM)

$-1.17

FCF margin

—

Effective tax rate

—

Per share

11 metrics

Revenue per diluted share (TTM)

—

Gross profit per diluted share (TTM)

—

Operating profit per diluted share (TTM)

—

EBITDA per diluted share (TTM)

—

Net income per diluted share (TTM)

—

Operating cash flow per diluted share (TTM)

—

Free cash flow per diluted share (TTM)

—

Capital expenditures per diluted share (TTM)

—

R&D per diluted share (TTM)

—

Stock compensation per diluted share (TTM)

—

Book value per share

—

Growth

11 metrics

Revenue growth YoY

-100.0%

Year over year

Net income growth YoY

—

Revenue (TTM)

$115,000

Trailing 12 months

EPS growth YoY

—

Shares change YoY

+8.4%

Year over year · more shares

Revenue CAGR (3Y)

—

Revenue CAGR (5Y)

—

EPS CAGR (3Y)

—

EPS CAGR (5Y)

—

FCF CAGR (3Y)

—

FCF CAGR (5Y)

—

Quality

14 metrics

Return on equity

—

Return on assets

—

Debt / equity

—

Current ratio

—

EBITDA (TTM)

—

Free cash flow (TTM)

—

Quick ratio

—

Interest coverage

—

Net debt / EBITDA

—

Return on invested capital

—

Trailing 12 months

Net cash

—

Latest balance sheet

Cash & equivalents

—

Total assets

—

Total debt

—

Cash flow & spend

7 metrics

Operating cash flow (TTM)

—

Capital expenditures (TTM)

—

R&D (TTM)

—

SG&A (TTM)

—

Stock compensation (TTM)

—

R&D / revenue

—

Stock compensation / revenue

—

Ownership (13F)

3 metrics

13F filers

33

13F filer change QoQ

-2

Institutional ownership

19.0%

Short interest

3 metrics

Short interest

7.7%

Latest settlement · 7.9 days to cover

Days to cover

7.9d

Short-squeeze score

67 / 100

Insider activity

2 metrics

Net insider buying (90D)

$24,206

Insider-sentiment score

79 / 100

Risk flags

1 metrics

Going concern

—

GRCE · Grace Therapeutics, Inc.

GRCE metrics

Market overview

Price action

Company

Valuation

Historical valuation

Dividends & buybacks

Earnings calendar

Profitability

Growth

Quality

Cash flow & spend

Ownership (13F)

Short interest

Insider activity

Risk flags

No metrics match that search